SMARCA4 and colorectal carcinoma: More importantly, we have shown that the SMARCA4-R1157W mutant enhanced SMARCA4 binding to PRMT1-mediated H4R3me2a, and increased its enrichment at the EGFR and TNS4 promoters, reinforcing their transcriptional expression and accelerating CRC progression.